Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on September 8th, 2017 by Betsy DavisPharma R&D
Figures released by the U.S. National Cancer Institute (NCI) in 2017 indicate that the burden of cancer is on the rise, with the number of diagnoses rising by 50% over the next 13 years. Even more troubling is the predicted mortality rate for cancer, Continue reading “Getting Personal: Better Diagnosis, Better Treatment” »
Posted on September 7th, 2017 by Christine de Vries - ScheideggerPharma R&D
Having access to a robust network of experts provides companies a real leg up in pursuing the most innovative approaches to drug discovery. When exploring unchartered territories such as new therapeutic areas or new molecules, Continue reading “Looking for the Best Scientific Minds to Partner With?” »
Posted on September 6th, 2017 by Dr Andrew A. ParsonsPharma R&D
Opinions matter; they can drive our behaviors. Within the context of Pharma R&D, it is important to harness the benefits of different views, to think outside the box, innovate and beat the safety of group thinking.
Posted on September 1st, 2017 by Prima SungPharma R&D
Now more than ever, even some of the largest companies are seeking out partnerships, finding advantages in them for both businesses, while also providing greater value for customers and the industry as a whole. Continue reading “Businesses and Customers Benefit From New Partnerships” »
Posted on August 30th, 2017 by Xuanyan XuPharmacovigilance
Healthcare has been in the spotlight for much of the year so far, as Congress has wrestled with the difficult question of how to make it both better and more affordable.
Posted on August 28th, 2017 by Patricia MorganPharma R&D
Every year, hundreds of thousands of people are diagnosed with melanoma, the most deadly form of skin cancer. Although rates of melanoma have continued to rise over the last three decades Continue reading “Selecting Anti-Melanoma Drug Targets” »
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.